No USFDA approval for Merck cough drug Gefapixant
New Delhi: Merck & Co said on Monday the U.S. Food and Drug Administration declined to approve its experimental drug for the treatment of chronic cough and sought additional information on its effectiveness.
The FDA's decision was not related to the drug's safety, Merck added.
The drugmaker said it would meet with the agency to discuss the next steps, without disclosing further details about the timeline. Shares of the company were down about 2.3% at $78.10.
The agency's decision could push back the approval of the oral drug gefapixant by several months, potentially helping Canada's Bellus Health Inc play catch up with its rival treatment candidate, BLU-5937.
"This setback could delay the launch for gefapixant potentially by six months to one year if no additional clinical trials are needed, and longer if another study is requested," Justin Zelin, analyst at BTIG, wrote in a note.
Meanwhile, Bellus in December reported positive results for BLU-5937 in a mid-stage study and the company had said it would start a late-stage trial in the second half of this year.
Read also: Pfizer-OPKO growth hormone deficiency treatment rejected by USFDA
Gefapixant and BLU-5937 target patients who have refractory chronic cough (RCC) which persists after the treatment of underlying health conditions such as asthma.
Chronic cough, which lasts more than eight weeks, is estimated to affect about 5% of adults in the United States, Merck said. RCC is a large target market with about nine million patients in the country and another nine million in Europe, according to Zelin.
Last week, Japan's health regulator approved gefapixant tablets for adults with refractory or unexplained chronic cough, to be marketed under the brand name Lyfnua.
Read also: USFDA halts use of Regeneron, Lilly Covid-19 antibody treatments
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.